459789-99-2 | Obetichloic acid

Packsize	Purity	Availability	Price	Discounted Price
25mg	95%	in stock	$39.00	$27.00
1g	98%	in stock	$45.00	$32.00
5g	98%	in stock	$139.00	$98.00

Description

• Catalog Number: AB47859
• Chemical Name: Obetichloic acid
• CAS Number: 459789-99-2
• Molecular Formula: C26H44O4
• Molecular Weight: 420.6252
• MDL Number: MFCD16621104
• SMILES: CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@@H]([C@@]3(C)CC[C@@H]2[C@@]2([C@H]1C[C@H](O)CC2)C)[C@@H](CCC(=O)O)C

Computed Properties

• Complexity: 649
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 11
• Heavy Atom Count: 30
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 5
• XLogP3: 5.7

Literature

• Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.

  Toxicology and applied pharmacology 20180601

• Steviol, an aglycone of steviol glycoside sweeteners, interacts with the pregnane X (PXR) and aryl hydrocarbon (AHR) receptors in detoxification regulation.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20171101

• Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system.

  Toxicology in vitro : an international journal published in association with BIBRA 20170301

• Dihydroartemisinin protects against alcoholic liver injury through alleviating hepatocyte steatosis in a farnesoid X receptor-dependent manner.

  Toxicology and applied pharmacology 20170115

• Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor.

  Toxicology letters 20170104

• Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation.

  Toxicology and applied pharmacology 20170101

• Pyrazinamide Induced Rat Cholestatic Liver Injury through Inhibition of FXR Regulatory Effect on Bile Acid Synthesis and Transport.

  Toxicological sciences : an official journal of the Society of Toxicology 20160801

• Obeticholic Acid: First Global Approval.

  Drugs 20160801

• Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice.

  The Journal of biological chemistry 20160129

• Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice.

  The Journal of pharmacology and experimental therapeutics 20121201

• An improved synthesis of 6α-ethylchenodeoxycholic acid (6ECDCA), a potent and selective agonist for the Farnesoid X Receptor (FXR).

  Steroids 20121101

• Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome.

  The Journal of steroid biochemistry and molecular biology 20121001

• Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20120701

• Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge Theonella swinhoei.

  Journal of medicinal chemistry 20120112

• Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit.

  The Journal of endocrinology 20120101

• FXR protects lung from lipopolysaccharide-induced acute injury.

  Molecular endocrinology (Baltimore, Md.) 20120101

• Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA.

  Mini reviews in medicinal chemistry 20110801

• Farnesoid X receptor agonists for primary biliary cirrhosis.

  Current opinion in gastroenterology 20110501

• Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease.

  Gut 20110401

• Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.

  Bioorganic & medicinal chemistry letters 20100815

• Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease.

  Circulation research 20100625

• Pharmacotherapy of cholestatic liver diseases.

  Journal of digestive diseases 20100601

• FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.

  Journal of lipid research 20100401

• Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.

  Journal of medicinal chemistry 20091224

• The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria.

  American journal of physiology. Renal physiology 20091201

• Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration.

  Arteriosclerosis, thrombosis, and vascular biology 20071201

• Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.

  Journal of medicinal chemistry 20070906

• The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution.

  American journal of physiology. Regulatory, integrative and comparative physiology 20070901

• The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo.

  Molecular pharmacology 20061001

• Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.

  Journal of medicinal chemistry 20060713

• Nuclear receptors, bile-acid detoxification, and cholestasis.

  Lancet (London, England) 20060211

• Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis.

  The Journal of pharmacology and experimental therapeutics 20051001

• A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis.

  The Journal of pharmacology and experimental therapeutics 20050801

• The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes.

  Molecular pharmacology 20050801

• Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis.

  The Journal of pharmacology and experimental therapeutics 20050501

• The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis.

  Gastroenterology 20041101

• The farnesoid X receptor: a novel drug target?

  Expert opinion on investigational drugs 20040901

• Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.

  Journal of medicinal chemistry 20040826

• Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR).

  Bioorganic & medicinal chemistry letters 20030602

• 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.

  Journal of medicinal chemistry 20020815

• Nuclear receptors and lipid physiology: opening the X-files.

  Science (New York, N.Y.) 20011130

• Identification of a nuclear receptor for bile acids.

  Science (New York, N.Y.) 19990521